All In Biotech

Drug Trial Radar · NCT00622648

Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin

International, Multi-center, Randomized, Double Blind Study to Compare the Overall Mortality in Acutely Ill Medical Patients Treated With Enoxaparin Versus Placebo in Addition to Graduated Elastic Stockings

Last checked: Nov 19, 2026Latest source record: Dec 28, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 8,329 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,329

Actual

Start

Jan 2008

Primary completion

Dec 2010

Study completion Dec 2010

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Feb 25, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective: * To demonstrate in patients hospitalized for an acute medical illness that enoxaparin with Graduated Elastic Stockings is superior to enoxaparin-placebo with Graduated Elastic Stockings on overall mortality at day 30 after randomization. The secondary objective: * To compare, in patients hospitalized for an acute medical illness, enoxaparin with Graduated Elastic Stockings versus enoxaparin placebo with Graduated Elastic Stockings on overall mortality at day 90 after randomization. * To evaluate the safety of enoxaparin VTE prophylaxis in patients hospitalized for acute medical illness with respect to major hemorrhage, total bleedings, heparin induced thrombocytopenia, adverse events and serious adverse events .

Conditions

  • Acute Illness

Interventions

  • EnoxaparinDrug

    40 mg once daily for 6 to 14 days (10 ± 4 days)

  • PlaceboDrug

    Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Death rate with all causes mortalityTime frame: At day 30
  2. HemorrhagesTime frame: Occuring until day 90

Locations

9 sites in 9 countries. Site status is shown where the registry gives one.

  • Sanofi-Aventis Administrative Office

    São Paulo, Brazil

  • Sanofi-Aventis Administrative Office

    Shanghai, China

  • Sanofi-Aventis Administrative Office

    Hong Kong, Hong Kong

  • Sanofi-Aventis Administrative Office

    Mumbai, India

  • Sanofi-Aventis Administrative Office

    Kuala Lumpur, Malaysia

  • Sanofi-Aventis Administrative Office

    Col. Coyoacan, Mexico

  • Sanofi-Aventis Administrative Office

    Makati City, Philippines

  • Sanofi-Aventis Administrative Office

    Seoul, South Korea

  • Sanofi-Aventis Administrative Office

    Mégrine, Tunisia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.